TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: HER2-expression analyzed from biopsy sample
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Bilateral Nasal Polyp Grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 10 year cardiac risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sustained Virologic Response 12 Weeks After Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Total Number of Participants Who Completed the Study-Related Ultrasound and MRI
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Participants With an Adjudicated Deep Vein Thrombosis (DVT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Presence of microbiologically confirmed active tuberculosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: ART outcome in patients taking concomitant anti-tuberculosis therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Target lesion reintervention (TLR) due to clinical recurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Difference between SpHb and SaHb values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Global Impression of Change (Patient)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Earliest Onset Day of Sexual Activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: CNS 1261 binding differences
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: trough plasma concentration (Cmin)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects responding to treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Without Progression or Death
Endpoint domain: Mortality/survival
Primary endpoint: incidence of new-onset diabetes mellitus (DM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: incidence of worsened diabetes mellitus (DM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction of ADHD-rating scale IV inattentive subscore
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Estimation of whole-body retention of radioactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Estimation of individual organ uptake/retention of radioactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Calculation of estimated absorbed radiation dose to target organs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of segments covered by contrast dye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change From Baseline in Whole Liver Fat at Week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in Hemoglobin A1c (HbA1c) at Week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Best response (CR or PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects with ALT levels over CTCAE grade II
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Number of Participants With Any Adverse Event (AE) and Serious Adverse Event (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Forced Expiratory Volume in One Second (FEV1) and Forced Vital Capacity (FVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Danirixin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Using an Effective Contraceptive Method 6 Weeks After Abortion
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: weekly epoetin beta dose per dry body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30% Improvement in Bowel Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Time spent in moderate-intensity physical activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Television watching time
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Total number of drinks consumed during the 5-day observation period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in liver function as indicated by ALT, AST
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of drop-outs due to adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: success of surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: condition of bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perianal pruritus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: degree of prolapse of internal hemorrhoids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amplitudes of muscle activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patellofemoral pain severity scale (PSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The visual analogue scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of YZJ-1139, zolpidem
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax of YZJ-1139, zolpidem
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: t1/2 of YZJ-1139, zolpidem
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of regorafenib + panitumumab
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Who Achieved Seroconversion or Significant Increase in SRH Area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Ratio of Participants Against Each of the Three Vaccine Strains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: migration of the prosthesis in millimeters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of Participants With Suppression of HBV DNA to < 2,000 IU/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients Who Become HBeAg Negative and Anti-HBe Positive
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Count of Patients Showing >25% Reduction in Cerebral Uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Breast sensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite Perinatal Outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Response Rate (Partial Response Plus Complete Response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: First Occurrence of Stroke
Endpoint domain: Mortality/survival
Primary endpoint: Intraoperative oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Truncal Fat Percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Abnormality in liver function test index (ALT, AST, TBil, GGT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Islet function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Global cognition score change
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Health-related quality of life (EQ-5D-5L)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Self-perceived health status (SF-12)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in pErbB3 levels in tumor tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: cycloplegic refraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-occlusive hyperaemia endothelium-dependent brachial artery dilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Achievement of haemostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of input-output of acupuncture needle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of local twitch response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Difference in Mean Patient Health Questionnaire 9 Score From Baseline
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 7-day point-prevalence tobacco abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rectal fever >39°C
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of appropriate antimicrobial initiation
Endpoint domain: Adverse events/effects
Primary endpoint: number of follicles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Size of follicle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Development of interstitial lung disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: sustained platelet response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: miR-155 expression in peripheral monocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in Rey Auditory Verbal Learning Test scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes in Face-Name Associative Memory Test scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: episiotomy requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: perineal tears
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Cognitive function composite score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Depression Diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nitrogen balance variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients that meet study ending criteria
Endpoint domain: Mortality/survival
Primary endpoint: Overall surgical morbidity
Endpoint domain: Adverse events/effects
Primary endpoint: High density lipoprotein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Human Papillomavirus (HPV) Clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: active tumor growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Asymptomatic bacteriuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Caregiver-child interaction quality
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: EQ5D-5L index
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Serum DAO Enzyme Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acquisition and maintenance of the control status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients achieving castration levels of plasma testosterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Proportion of patients maintaining castration levels of plasma testosterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Proportion of patients showing acute rises in plasma testosterone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Proportion of fat oxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: maximum tolerated dose of JNJ-26481585
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: safety of JNJ-26481585
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Gingivitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: complete resolution of respiratory symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Safety of cryoablation
Endpoint domain: Adverse events/effects
Primary endpoint: Blood transfusion
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Intra-op diastolic function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Successful Revascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Regression Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants With One or More Treatment-Emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electrocardiography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Self reported quality of sleep
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Measured quality of sleep
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Viral load measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Home visit assessment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence of severe diarrhea toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of severe hand-foot syndrome toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Tegner activity score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percent Change From Baseline in Non-HDL-C at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cell Markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Halitosis Measured by Organoleptic Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Halitosis Measured by Halimeter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved picture naming of trained words
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: AUCF 0-360 min of serum insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Fatigue Resistance Factor
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Occurrence of Helicobacter pylori infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Amount of morphine used
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: pain score 12h post operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients achieving GDMT titration completion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of clinic visits required to achieve GDMT titration completion
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of Patients Consenting to Enrollment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Abstinence at the end of the 2-year intervention period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overground gait speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Polyp prediction accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Time Interval Between Infusions During Maintenance Therapy
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Median Time Interval Between Infusions During Maintenance Therapy
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Average Dose During Induction Therapy and Subsequent Maintenance Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Dystrophin Level (% Normal Dystrophin)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in North Star Ambulatory Assessment (NSAA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hamilton Depression Rating Scale Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Postprandial Change in Flow Mediated Dilatation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Accuracy of blood glucose level estimation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Occurrence of Suboptimal PIFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analog Scale for Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with complete hybrid procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of conversion to standard CABG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Occurrence of MACE (death, MI, stroke, TVR, major bleeding)
Endpoint domain: Adverse events/effects
Primary endpoint: Acute vascular function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Long-term vascular function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Rhinitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Atopic Dermatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Food Allergy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specific Immunoglobulin E (IgEs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Infants' pain response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of mitral regurgitation severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in mitral annulus geometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in number of metastatic lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Binocular Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severe desaturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: surgical training overtime
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: delays in the operating theatre
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: mental demand overtime when operating
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: operative timings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Participants With Any COPD-Related Exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Forward shoulder posture after intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concordance between satisfaction level and quality of life assessment
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in global and disease-specific QOL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in muscular strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in maximal aerobic capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normalization of telomerase activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference of SBP ARV and MAP ARV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With Positive Immunological Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Immune response assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Average concentration of ipilimumab (Cavg21d)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration in ipilimumab AUC(0-21d)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes